RxDoctor Payments Data

Katherine Haseltine, MD

Internal Medicine · New York, NYNPI 1053792671

Payments from drug & device makers

$1,397in general payments, 2019–2025

Across 58 payments — averaging $24.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Radius Health, Inc.$318
  • Lilly USA, LLC$209
  • Novo Nordisk$179
  • Amgen$133
  • Alvogen Inc$127
  • Mannkind Corporation$125
  • plus $306 from 5 others

What the payments were for

  • Food & beverage$1,397100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,397 in reported general payments places this provider in the 75th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$22,663
Medicare patients
115
Services billed
371

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TymlosAbaloparatide94$247,582
ForteoTeriparatide22$101,652
Teriparatide24$79,630
OzempicSemaglutide15$17,932
Risedronate Sodium19$923
Alendronate Sodium119$637
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic13$625
Levothyroxine Sodium22$223
Calcitriol13$141

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Radius Health, Inc.Tymlos$318$247,58294 claims
Lilly USA, LLCForteo$209$101,65222 claims
Alvogen IncTeriparatide$127$79,63024 claims
Novo NordiskOzempic$179$17,93215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →